Latest News and Press Releases

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated...

Longeveron announces closing of up to $17.5 million public offering. Proceeds to support potential BLA readiness activities, among other items.

Longeveron announces the pricing of a public offering of common stock and warrants.

Longeveron will report Q2 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close.

Longeveron licenses patented stem cell technology from the University of Miami.

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.

Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).

Longeveron CEO Wa’el Hashad will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.